Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436723 | 0.95 | MAOA (0.41) | ALDH1A1MAOAMAOBTDP2IDO1 | |
| SCHEMBL435253 | 0.93 | MAOA (0.42) | ALDH1A1MAOAMAOBTDP2IDO1 | |
| SCHEMBL434353 | 0.91 | ALDH1A1 (0.42) | ALDH1A1MAOAMAOBTDP2IDO1 | |
| SCHEMBL28289816 | 0.82 | CA9 (0.39) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL434517 | 0.78 | KMO (0.38) | KMT2AHPGDCYP11B1CYP11B2KMO | |
| SCHEMBL9135463 | 0.77 | ALDH1A1 (0.52) | ALDH1A1IDO1AGXTKDM4EKMT2A | |
| SCHEMBL8640755 | 0.75 | PARP1 (0.40) | ALDH1A1TDP2 | |
| SCHEMBL433557 | 0.74 | KMT2A (0.41) | KMT2ACYP19A1CYP11B1CYP11B2KMO | |
| SCHEMBL17514969 | 0.74 | NISCH (0.46) | KDM4ESMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL19994059 | 0.72 | NISCH (0.45) | ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595985-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595984-A1 | MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010568-A1 | MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010567-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | ALDH1A1 2969/4885MAOA 4705/4885MAOB 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.